The issue is, whilst NUH may have demanded the co-development fee ( and who knows if that is actually true ) , they had to borrow money they did not have to pay a co-development fee, whereas all they had to do was do a short term license agreement with RT, take the royalty fees for a year or two, then do it when they had the cash to themselves to pay for it, without jeopardising the company and shareholders money. Your argument you put forward is fine if the company is in a cash positive situation, but it never has been, nor unlikely ever will be now.
It is hugely telling that the Alango/realtek solution is now ready for the African hearing market, laxi/realtek for india market, rehear/relatek/audeara taiwan, and yet realtek are a strategic partner and cornerstone of nuheara, yet have no deals to date and have fixed and floating charges ? It makes no sense to me, nor many others on here. Not one deal, not one MOU, not once cent has come back in two years from this agreement, and all money in has gone back to realtek , so why would that be? Nothing to do with FDA, as it can go into PSAP or any CE equipment.
- Forums
- ASX - By Stock
- NUH
- Ann: March 2024 Quarterly Appendix 4C
Ann: March 2024 Quarterly Appendix 4C, page-74
-
- There are more pages in this discussion • 193 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NUH (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.91M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
NEWS
Gold nuggets unearthed at Comet Well ahead of drilling! Discoveries continue as exploration ramps up
RCE
Phase II clinical trial recruitment for R327G topical gel passes halfway, showing promising results against bacterial skin infections
NUH (ASX) Chart |
Day chart unavailable
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online